Compare AbbVie Inc (ABBV) vs FedEx Corporation (FDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs FedEx Corporation — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while FedEx Corporation trades at $308.55 (market cap $74.66B). The key difference: AbbVie Inc is far larger — about 6× FedEx Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | FDX | |
|---|---|---|
Market Cap | $449.91B | $74.66B |
Sector | Health | Industrials |
52-Week High | $261.07 | $338.75 |
52-Week Low | $184.85 | $174.81 |
Enterprise Value | $513.38B | $108.67B |
Dividend Yield | 2.72% | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
FedEx trades at $312.88, down slightly by 0.04% on the day, with a bearish technical signal from moving averages. Recent quarterly earnings have consistently beaten expectations, including Q1 2026 EPS of $6.31 versus $5.91 expected. The company is streamlining operations, highlighted by the sale of its supply chain unit to CMA CGM for $1.4 billion, while maintaining solid cash flow from operations of $7.04 billion in 2025.
The outlook is mixed: analyst consensus is bullish with a $365.73 price target, but margin recovery remains uncertain. Key risks include soft shipping demand and ongoing cost pressures. Upside potential hinges on successful execution of efficiency initiatives like DRIVE and Network 2.0 to expand profitability beyond current 4.88% net margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
